The growth of CLASRP-overexpressing CRC cells was significantly suppressed by the inhibitors TG003 and KH-CB19, and the inhibition ratio increased gradually in a dose-dependent manner (P < 0.001; Fig. 4a, b). Here, CLASRP is linked to colorectal carcinoma.